Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study.
To investigate the epidemiology of systemic sclerosis (SSc) in southern Europe, we assessed the incidence, prevalence, clinical spectrum, and survival of patients diagnosed with SSc in the Lugo region of northwestern Spain. Between January 1988 and December 2006, SSc was diagnosed in 78 Lugo residents according to the criteria proposed by LeRoy and Medsger and/or the 1980 American College of Rheumatology (ACR) preliminary criteria for the classification of SSc. However, only 44 (56.4%) of the 78 patients fulfilled the 1980 ACR criteria for the classification of SSc. The mean age at the time of disease diagnosis was 59.8 +/- 13.3 years. Twenty-three (29.5%) met definitions for diffuse SSc (dSSc), and 55 (70.5%) for limited SSc (lSSc). Patients with lSSc had a longer disease duration before the diagnosis (10.2 +/- 12.0 yr) than those with dSSc (3.7 +/- 3.2yr) (p < 0.001). Based on the criteria proposed by LeRoy and Medsger and/or the 1980 ACR criteria for the classification of SSc, the overall age- and sex-adjusted annual incidence rate over the 19-year study period was 2.3 (95% confidence interval [CI], 1.6-2.5) per 100,000 population aged 15 yr and older (women: 3.5 [95% CI, 2.3-3.9]; men: 1.0 [95% CI, 0.5-1.4]; p < 0.001). Using only the 1980 ACR criteria for SSc, the total annual-adjusted incidence rate was 1.2 (95% CI, 0.9-1.6) per 100,000 population aged 15 years and older (women: 1.8 [95% CI, 1.2-2.5]; men: 0.7 [95% CI, 0.3-1.2]; p < 0.001). The incidence increased significantly in individuals aged 45 years or older. The overall incidence rates of SSc increased over the length of the study (p for trend in the total incidence < 0.001). This was mainly due to a progressive increase of SSc in women between 1993 and 2002. By December 31, 2006, the overall age-adjusted SSc prevalence in the Lugo region of patients who met the criteria proposed by LeRoy and Medsger and/or the 1980 ACR criteria was 27.7 (95% CI, 21.1-35.84) per 100,000 population aged 15 years and older. Cardiopulmonary complications were the leading cause of death (13 of 20 cases). Compared with that in the general population, the probability of survival in patients with SSc was significantly reduced (p < 0.001).The current study establishes a baseline estimate of the incidence and clinical spectrum of SSc in northwestern Spain. According to our results, the incidence and prevalence of SSc in northwestern Spain are similar to those found in Greece and some regions of the United States. Our data confirm a reduced probability of survival in patients with SSc.
Arias-Nuñez
Maria C
MC
From Divisions of Internal Medicine (MCA-N), Rheumatology (TRV-R, JAM-F, MAG-G), and Cardiology (CG-J), Hospital Xeral-Calde, Lugo; Division of Epidemiology and Computational Biology (JL, IG-A), School of Medicine, University of Cantabria, Santander; and Consejo Superior de Investigaciones Cientificas (JM), Granada, Spain.
Llorca
Javier
J
Vazquez-Rodriguez
Tomas R
TR
Gomez-Acebo
Ines
I
Miranda-Filloy
Jose A
JA
Martin
Javier
J
Gonzalez-Juanatey
Carlos
C
Gonzalez-Gay
Miguel A
MA
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000453:epidemiology* / Q000401:mortality; D013030:Spain / Q000453:epidemiology; D011795:Surveys and Questionnaires; D015996:Survival Rate; D013997:Time Factors
Airò P, Tabaglio E, Frassi M, Scarsi M, Danieli E, Rossi M. Prevalence of systemic sclerosis in Valtrompia in northern Italy. A collaborative study of rheumatologists and general practitioners. Clin Exp Rheumatol. 2007;25:878-880.
Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA, Drosos AA. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum. 2005;34:714-720.
Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford). 2004;43:596-602.
Chandran G, Smith M, Ahern MJ, Roberts-Thomson PJ. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. Aust N Z J Med. 1995;25:688-694.
Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4:87-90.
Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81:139-153.
Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med. 1980;69:520-526.
Garcia-Porrua C, Gonzalez-Gay MA. Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schonlein purpura in adults. Semin Arthritis Rheum. 1999;28:404-412.
García-Porrúa C, Gonzalez-Gay MA, Vázquez-Caruncho M, López-Lazaro L, Lueiro M, Fernández ML, Alvarez-Ferreira J, Pujol RM. Erythema nodosum: etiologic and predictive factors in a defined population. Arthritis Rheum. 2000;43:584-592. Erratum in: Arthritis Rheum. 2000;43:1061.
Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis. 1994;53:502-505.
Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum. 2004;33:289-293.
Gonzalez-Gay MA, Blanco R, Abraira V, Garcia-Porrua C, Ibañez D, Garcia-Pais MJ, Rigueiro MT, Sanchez-Andrade A, Guerrero J, Casariego E. Giant cell arteritis in Lugo (Spain) is associated with a low long-term mortality. J Rheumatol. 1997;24:2171-2176.
Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997: clinical and epidemiologic aspects. Medicine (Baltimore). 1999;78:292-308.
Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum. 2003;49:388-393.
Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, Ollier WE, Martin J, Llorca J. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57:125-132.
Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Ollier WE, Gonzalez-Gay MA. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2004;33:231-238.
Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford). 2004;43:1129-1137.
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205.
LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-1576.
Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, Choquette D, Raymond Y, Senécal JL. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 2001;44:735-736.
Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, LeRoy EC, McGregor AR, Diat F, Rosal EJ. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum. 1989;32:998-1006.
Mayes MD. Epidemiology of systemic sclerosis and related diseases. Curr Opin Rheumatol. 1997;9:557-561.
Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003;29:239-254.
Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246-2255.
Mayes MD, Laing TJ, Gillespie BW, Cooper BC, Lacey JV Jr, Hirschenberger WS, Atty SM, Schottenfeld D. Prevalence, incidence and survival rates of systemic sclerosis in the Detroit metropolitan area [abstract]. Arthritis Rheum. 1996;39:S150.
Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985;60:105-113.
Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000;43:444-451.
Roberts-Thomson PJ, Jones M, Hakendorf P, Kencana Dharmapatni AA, Walker JG, MacFarlane JG, Smith MD, Ahern MJ. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J. 2001;31:220-229.
Silman AJ. Scleroderma-demographics and survival. J Rheumatol. 1997;48(suppl):58-61.
Silman AJ, Howard Y, Hicklin AJ, Black C. Geographical clustering of scleroderma in south and west London. Br J Rheumatol. 1990;29:93-96.
Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol. 1988;27:286-290.
Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum. 1997;40:441-445.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-590.
Tamaki T, Mori S, Takehara K . Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res. 1991;283:366-371.
Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980;23:617-625.
Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am. 2003;29:211-237.
Walker JG, Pope J, Baron M, Leclercq S, Hudson M, Taillefer S, Edworthy SM, Nadashkevich O, Fritzler MJ. The development of systemic sclerosis classification criteria. Clin Rheumatol. 2007;26:1401-1409.
Wigley FM. When is scleroderma really scleroderma? J Rheumatol. 2001;28:1471-1473.